Sugi Predict

Sugi Predict / Compounds / SCHEMBL2035181

SCHEMBL2035181

SCHEMBL2035181

CC(O)c1cc(Cl)c2conc2c1-c1cccc(F)c1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 5/20 0.40
▸ BCL2 P10415 1/20 0.39
▸ NT5E P21589 1/20 0.34
▸ BRD4 O60885 2/20 0.33
▸ KCNH2 Q12809 1/20 0.33
▸ BRD2 P25440 1/20 0.33
▸ CREBBP Q92793 1/20 0.33
▸ GCGR P47871 1/20 0.32
▸ AXL P30530 1/20 0.32
▸ MERTK Q12866 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ TP53 P04637 1/20 0.31
▸ GPBAR1 Q8TDU6 1/20 0.31
▸ TRPM8 Q7Z2W7 1/20 0.31
▸ ACLY P53396 1/20 0.31
▸ GRIN2B Q13224 1/20 0.30
▸ GRM5 P41594 1/20 0.30
▸ RPS6KB1 P23443 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2037421 0.88 BCL2 (0.41) PIK3CDBCL2NT5EGCGRAXL
SCHEMBL12470347 0.85 PIK3CD (0.38) PIK3CDBCL2NT5EAXLMERTK
SCHEMBL15621559 0.85 PIK3CD (0.38) PIK3CDBCL2NT5EBRD4AXL
SCHEMBL15617777 0.83 BCL2 (0.38) PIK3CDBCL2NT5E
SCHEMBL2166300 0.82 PIK3CD (0.36) PIK3CDBCL2GRM5
SCHEMBL2039744 0.80 NT5E (0.36) PIK3CDNT5EGCGRTP53ACLY
SCHEMBL2019258 0.79 PIK3CD (0.58) PIK3CDBCL2NT5EKCNH2GCGR
SCHEMBL2163762 0.79 PIK3CD (0.58) PIK3CDBCL2NT5EKCNH2GCGR
SCHEMBL2018513 0.76 NT5E (0.38) NT5EBRD4SMN1; SMN2ACLYGRM5
SCHEMBL2013792 0.75 PIK3CD (0.59) PIK3CDBCL2AXLMERTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680108-B2 Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors INCYTE CORPORATION (US) 2014-03-25 — — US disclosed
US-8680108-B2 Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors INCYTE CORPORATION (US) 2014-03-25 — — US disclosed
US-8680108-B2 Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors INCYTE CORPORATION (US) 2014-03-25 — — US disclosed
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION 2011-07-28 — — US disclosed
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION 2011-07-28 — — US disclosed
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION 2011-07-28 — — US disclosed
WO-2011075630-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION (US) 2011-06-23 — — WO disclosed
WO-2011075630-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION (US) 2011-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS PIK3R1, PIK3R3, PIK3R2 PIK3CD 13/4885BCL2 1174/4885NT5E 4372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.